About: Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 05 January 2016

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2016 (ast) наукова стаття, опублікована в січні 2016 (uk) مقالة علمية نشرت في 05 يناير 2016 (ar) scientific article published on 05 January 2016 (en)
publication date	wds:Q37398907-237E36E0-8B88-4E51-A72D-C16FC3966AC3
publication date	2016-01-05 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37398907-8147BE46-7CF0-4425-8D58-A7BBE1B8001A
language of work or name	English
cites work	wds:Q37398907-03C68177-4FE6-4296-BCB5-B8F285A14D72 wds:Q37398907-05C6F217-50DF-4787-B0F9-E6B43E711EBB wds:Q37398907-10104D59-C9E0-4BAB-A99E-AAFC699D1AAC wds:Q37398907-1DD496FE-9B30-4185-A18D-1FBFC7FDFCFC wds:Q37398907-3BBDF36C-E2C7-4292-B640-E29DA1A2A70A wds:Q37398907-521F7109-49B9-44E5-8C89-19C0EDA8ED8D wds:Q37398907-5764F9AB-1BD8-4CEA-914B-871F56EC4E57 wds:Q37398907-5A54AB33-2C5B-4894-9CFB-6E1DBAD684E9 wds:Q37398907-5F39047F-1BDE-4971-8852-C38C0DF36452 wds:Q37398907-5F75F50D-A9BC-40F3-B7F3-05364AAF3F65 wds:Q37398907-660BE344-37AA-4A0F-8F08-2F4D9590D29F wds:Q37398907-675FDFCE-7401-4447-A254-506ED4EDB1D4 wds:Q37398907-807AA137-D297-4925-8D0A-2A91D04F0485 wds:Q37398907-9090C675-9118-4DCA-965A-104F5586303C wds:Q37398907-92C94F31-C77F-496B-B0DD-39356F3251C0 wds:Q37398907-92E0F13D-801A-4857-A106-7779CB2C23C5 wds:Q37398907-BF0C549F-C669-426D-9270-27D4C9EFCCDB wds:Q37398907-C0E3F6CC-6D54-4985-8B3F-283F856C69C7 wds:Q37398907-D5F34927-E83F-4053-B189-0AB8855260E1
cites work	Treating rheumatoid arthritis to target: recommendations of an international task force Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Revolutionary change in rheumatoid arthritis management with biological therapy
author name string	wds:Q37398907-03B673C5-6D0D-49F9-9836-A1068263090B wds:Q37398907-1491EE8F-5791-4A52-8373-9B842EF2DB62 wds:Q37398907-1985EA99-5036-4BFE-B857-FF1F5F9003FD wds:Q37398907-1A6CE72D-E443-4DD4-A3AF-84C315E86BF1 wds:Q37398907-39F01214-F1BB-410C-AF21-ED7D2AEDB78A wds:Q37398907-4F382CF0-5483-42C4-B972-E72D3F157B4C wds:Q37398907-57E20502-67A3-4152-8C2D-D106A8970B82 wds:Q37398907-AD1B01F3-50F2-4CFD-B3C4-8AFED0A721D7 wds:Q37398907-AF24CBEC-DDC2-42DF-A104-1C77C61DB89B wds:Q37398907-B798C755-8DB6-484E-AE32-BA8EF789F00B wds:Q37398907-BAC93575-D2A9-4063-92D7-435044A6DC09 wds:Q37398907-C7CFE3AA-4671-4724-8941-97C9688290A3 wds:Q37398907-EE2E3D86-13F5-4DDD-A0E9-8DF1FB560BF4 wds:Q37398907-F01387B5-4D72-4793-AD59-7E8BCF20D628
author name string	Tatsuya Atsumi Eiichi Tanaka Yoshiya Tanaka Kazuhiko Yamamoto Hidekata Yasuoka Nobuyuki Miyasaka Hayato Nagasawa Shintaro Hirata Yuko Kaneko Yohko Murakawa Koichi Amano Masayuki Miyata Masayuki Inoo Hitomi Kobayashi-Haraoka
rdfs:label	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). (en) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). (nl) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). (ast)
skos:prefLabel	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). (en) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). (nl) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). (ast)
name	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). (en) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). (nl) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). (ast)
author	wds:Q37398907-42C46CF1-6C64-4B43-A9CD-77A3DE5A9E78 wds:Q37398907-7A1F0326-18DD-4ED6-82B0-68B56E3DFFA4
author	Hisashi Yamanaka Tsutomu Takeuchi

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software